NCT06489457View on ClinicalTrials.gov

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

May 11, 2023

Study Completion Date

June 30, 2023

Conditions
Type 2 Diabetes MellitusObesityFunctional Hypogonadism
Interventions
DRUG

Semaglutide

Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)

DRUG

Testosterone Undecanoate

Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks

Trial Locations (1)

1000

University Medical Centre Ljubljana, Ljubljana

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER

NCT06489457 - The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity | Biotech Hunter | Biotech Hunter